MARKET

MIST

MIST

Milestone Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.57
+1.37
+8.46%
Closed 16:00 10/11 EDT
OPEN
16.44
PREV CLOSE
16.20
HIGH
18.39
LOW
16.44
VOLUME
6.68K
TURNOVER
--
52 WEEK HIGH
27.95
52 WEEK LOW
15.09
MARKET CAP
406.70M
P/E (TTM)
-39.7511
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MIST and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MIST News

  • Milestone Pharmaceuticals Announces First Patient Enrolled in NODE-303 Open-label Safety Study of Etripamil in PSVT
  • CNW Group.10/03 12:00
  • Milestone Pharma Reports First Patient Enrolled In NODE-303 Study Of Etripamil In PSVT
  • Benzinga.10/03 11:08
  • Milestone Pharmaceuticals begins etripamil study
  • Seeking Alpha - Article.10/03 11:05
  • New finance chief at Milestone Pharma
  • seekingalpha.09/10 16:03

More

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.89%

Hot Stocks

Name
Price
%Change

About MIST

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.
More

Webull offers Milestone Pharmaceuticals Inc (MIST) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.